source
- Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersThe FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.BioPharma Dive · 5h ago↗ source
- Taiho and Cullinan report positive Phase 3 results for zipalertinib in EGFR exon 20 insertion lung cancerTaiho Oncology and Cullinan Therapeutics announced that their experimental drug zipalertinib achieved positive results in a Phase 3 trial for first‑line treatment of lung cancer patients whose tumo…